Overview

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.
Phase:
Phase 1
Details
Lead Sponsor:
Warner Chilcott
Collaborator:
Sanofi
Treatments:
Alendronate
Etidronic Acid
Risedronate Sodium
Risedronic Acid